Palvella Therapeutics, Inc. (PVLA)

NCM – Real vaqt narxi. Valyuta: USD

125.79

+3.70 (3.03%)

Yopilishda: May 12, 2026, 4:00 PM EDT

08.05.2026

Palvella Therapeutics Q1 Earnings Call Highlights

Palvella Therapeutics NASDAQ: PVLA said it remains on track to submit a New Drug Application in the second half of 2026 for QTORIN rapamycin in Microcystic Lymphatic Malformations, after reporting what executives described as positive Phase 3 results and outlining an expanded commercial plan supported by a recent $230 million financing.

08.05.2026

Palvella Therapeutics, Inc. (PVLA) Q1 2026 Earnings Call Transcript

07.05.2026

Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

FDA Pre-New Drug Application (NDA) meeting granted for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, with meeting expected in second quarter of 2026; NDA submission on track for second half of 2026 Accelerating U.S. launch readiness for QTORIN™ rapamycin for microcystic lymphatic malformations; BEYONDmLM.com disease awareness campaign launched to educate, engage, and empower patients, caregivers, and healthcare professionals Initiation of Phase 3 trial of QTORIN™ rapamycin for the treatment of cutaneous venous malformations planned for second half of 2026 Initiation of Phase 2 trial of QTORIN™ pitavastatin for the treatment of disseminated superficial actinic porokeratosis planned for second half of 2026 Phase 2 LOTU trial of QTORIN™ rapamycin for clinically significant angiokeratomas initiated with topline results expected in second half of 2027 Completed upsized, oversubscribed equity financing of $230.0 million in February 2026; cash, cash equivalents and short-term investments of $261.9 million as of March 31, 2026 Company to host conference call at 8:30 a.m. ET today WAYNE, Pa.

04.05.2026

Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas

Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA-approved therapies and an estimated more than 50,000 diagnosed patients in the U.S.

30.04.2026

Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026

WAYNE, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it will report its first quarter 2026 financial results before market open on Thursday, May 7, 2026. Palvella management will host a conference call for investors at 8:30 a.m. ET on that same day to discuss the results and provide a corporate update.

20.04.2026

Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026

James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children's Hospital of Philadelphia to present clinical results on Wednesday, May 20, 2026, at 4:30 p.m. ET

13.04.2026

Palvella Therapeutics Appoints John D. Doux, M.D.

Physician and seasoned life sciences investor with more than two decades of experience across clinical practice, biotechnology investing, and board leadership

Videolar

No Data

There is no data to display

Press-relizlar

07.05.2026

Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

04.05.2026

Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas

Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA-approved therapies and an estimated more than 50,000 diagnosed patients in the U.S.

13.04.2026

Palvella Therapeutics Appoints John D. Doux, M.D.

Physician and seasoned life sciences investor with more than two decades of experience across clinical practice, biotechnology investing, and board leadership

07.04.2026

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (Nasdaq: ARQT), where he led U.S. sales efforts for ZORYVE®, a next-generation topical PDE4 inhibitor; previously, he held leadership roles at Incyte (Nasdaq: INCY) supporting the launch of OPZELURA®

Palvella Therapeutics, Inc. (PVLA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Palvella Therapeutics, Inc. (PVLA)

Palvella Therapeutics Q1 Earnings Call Highlights

Palvella Therapeutics, Inc. (PVLA) Q1 2026 Earnings Call Transcript

Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas

Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026

Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026

Palvella Therapeutics Appoints John D. Doux, M.D.

Videolar

No Data

Press-relizlar

Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas

Palvella Therapeutics Appoints John D. Doux, M.D.

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

Palvella Therapeutics Q1 Earnings Call Highlights

Palvella Therapeutics, Inc. (PVLA) Q1 2026 Earnings Call Transcript

Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas

Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026

Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026

Palvella Therapeutics Appoints John D. Doux, M.D.

Videolar

No Data

Press-relizlar

Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas

Palvella Therapeutics Appoints John D. Doux, M.D.

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

Search stocks

Palvella Therapeutics, Inc. (PVLA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Palvella Therapeutics, Inc. (PVLA)

Palvella Therapeutics Q1 Earnings Call Highlights

Palvella Therapeutics, Inc. (PVLA) Q1 2026 Earnings Call Transcript

Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas

Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026

Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026

Palvella Therapeutics Appoints John D. Doux, M.D.

Videolar

No Data

Press-relizlar

Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas

Palvella Therapeutics Appoints John D. Doux, M.D.

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

Palvella Therapeutics Q1 Earnings Call Highlights

Palvella Therapeutics, Inc. (PVLA) Q1 2026 Earnings Call Transcript

Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas

Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026

Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026

Palvella Therapeutics Appoints John D. Doux, M.D.

Videolar

No Data

Press-relizlar

Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas

Palvella Therapeutics Appoints John D. Doux, M.D.

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales